Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Gasherbrum Bio General Information
Gasherbrum Bio is developing orally available small molecule GLP‑1 receptor agonists. Its lead candidate, aleniglipron (GSBR‑1290), has reached Phase 2 clinical trials for obesity and type 2 diabetes. Preclinical work is ongoing in Parkinson’s disease. Clinical results to date have not been published in detail, but multiple Phase 2 studies are active or recently completed.
Contact Information
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Structure Therapeutics
Gasherbrum Bio Funding
No funding data available
To view Gasherbrum Bio's complete valuation and funding history, request access »